Summary & Overview
HCPCS M1408: Germline BRCA Testing Before Ovarian Cancer Diagnosis
HCPCS Level II code M1408 denotes patients who completed germline BRCA testing prior to diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Nationally, documenting pre-diagnostic BRCA status informs genetic risk assessment, eligibility for targeted therapies, and care planning across oncology and genetic counseling services. Clear coding supports care coordination and appropriate use of PARP inhibitors and other precision therapies when clinically indicated.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the clinical context for pre-diagnostic BRCA testing, common sites of service where this status is documented, and typical billing considerations tied to documenting prior genetic testing. The publication also summarizes benchmarking elements and policy implications that affect coverage and documentation of pre-existing germline testing status.
This summary is intended for a national audience of payers, provider billing staff, and policy analysts seeking concise guidance on the clinical meaning and administrative relevance of HCPCS Level II code M1408. Data not available in the input for associated taxonomies, ICD-10 mappings, and related billing codes are noted where applicable.
Billing Code Overview
HCPCS Level II code M1408 describes patients who have germline BRCA testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer. This code represents identification of a pre-diagnostic genetic testing status relevant to hereditary cancer evaluation.
-
Service type: Documentation/clinical status related to prior genetic testing
-
Typical site of service: Oncology clinics, gynecologic oncology practices, genetic counseling clinics, and other outpatient settings where cancer diagnostic evaluation and treatment planning occur.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 52-year-old woman with a known deleterious germline BRCA1 pathogenic variant identified during prior hereditary cancer testing presents after detection of an adnexal mass on pelvic imaging. She is referred to gynecologic oncology for evaluation and management of suspected epithelial ovarian carcinoma. Her medical record documents prior BRCA testing completed before the current cancer diagnosis. The clinical workflow includes review of prior genetic test reports, confirmation of germline BRCA status in the oncology chart, multidisciplinary tumor board discussion, preoperative counseling addressing targeted therapy eligibility (PARP inhibitors) and hereditary cancer implications for family members, and documentation of prior testing as part of treatment planning and payer verification for coverage of genotype-directed therapies.
Typical site of service: Outpatient oncology clinic or gynecologic oncology clinic; results and prior testing may be reviewed in inpatient admission if the patient is hospitalized for surgery. Service type: Medical record review and verification of pre-diagnostic germline BRCA testing to support cancer-directed treatment decisions and billing under the HCPCS Level II descriptor.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when documented work or complexity for review and coordination (beyond typical) is substantially greater due to complex genetics or extensive chart review. |